Satoshi Muto

Dr. Satoshi Muto

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
YOYuki Owada-Ozaki
Yuki Owada-Ozaki
SMSatoshi Muto
Satoshi Muto
HTHironori Takagi
Hironori Takagi
TITakuya Inoue
Takuya Inoue
YWYuzuru Watanabe
Yuzuru Watanabe
HSHiroyuki Suzuki
Hiroyuki Suzuki

12 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SMSatoshi Muto
Satoshi Muto
AEAkio Enta
Akio Enta
YMYoshiyuki Maruya
Yoshiyuki Maruya
SISho Inomata
Sho Inomata
HYHikaru Yamaguchi
Hikaru Yamaguchi
HSHiroyuki Suzuki
Hiroyuki Suzuki
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody and chemotherapy, or an anti-PD-1/PD-L1 antibody and an anti-CTLA-4 antibody with or without chemotherapy. Although there were fewer cases of disease progression in the early stages of combination treatment than with anti-PD-1/PD-L1 antibodies alone, only approximately half of the patients had a long-term response. Therefore, it is necessary to elucidate the mechanisms of resistance to immune checkpoint inhibitors. Recent reports of such mechanisms include reduced cancer-cell immunogenicity, loss of major histocompatibility complex, dysfunctional tumor-intrinsic interferon-γ signaling, and oncogenic signaling leading to immunoediting. Among these, the Wnt/β-catenin pathway is a notable potential mechanism of immune escape and resistance to immune checkpoint inhibitors. In this review, we will summarize findings on these resistance mechanisms in NSCLC and other cancers, focusing on Wnt/β-catenin signaling. First, we will review the molecular biology of Wnt/β-catenin signaling, then discuss how it can induce immunoediting and resistance to immune checkpoint inhibitors. We will also describe other various mechanisms of immune-checkpoint-inhibitor resistance. Finally, we will propose therapeutic approaches to overcome these mechanisms.

20 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
NTNobuhiko Takahashi
Nobuhiko Takahashi
HHHirotaka Hoshi
Hirotaka Hoshi
AHArisa Higa
Arisa Higa
GHGen Hiyama
Gen Hiyama
HTHirosumi Tamura
Hirosumi Tamura
MTMotoki Takagi
Motoki Takagi
Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established PDOs from various human tumors to accurately and efficiently recapitulate the tissue architecture and function. Molecular targeted therapies with remarkable efficacy are currently in use against various tumors. Thus, there is a need for in vitro functional-potency assays that can be used to test the efficacy of molecular targeted drugs and model complex interactions between immune cells and tumor cells to evaluate the potential for cancer immunotherapy. This study represents an in vitro evaluation of different classes of molecular targeted drugs, including small-molecule inhibitors, monoclonal antibodies, and an antibody-drug conjugate, using lung PDOs. We evaluated epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) inhibitors using a suitable high-throughput assay system. Next, the antibody-dependent cellular cytotoxicity (ADCC) activity of an anti-HER2 monoclonal antibody was evaluated to visualize the interactions of immune cells with PDOs during ADCC responses. Moreover, an evaluation system was developed for the immune checkpoint inhibitors, nivolumab and pembrolizumab, using PDOs. Our results demonstrate that the in vitro assay systems using PDOs were suitable for evaluating molecular targeted drugs under conditions that better reflect pathological conditions.

1 June 2015 in Lung Cancer
Verified
Journal Article
Closed access
JOJun Osugi
Jun Osugi
TYTakumi Yamaura
Takumi Yamaura
SMSatoshi Muto
Satoshi Muto
NONaoyuki Okabe
Naoyuki Okabe
YMYuki Matsumura
Yuki Matsumura
MGMitsukazu Gotoh
Mitsukazu Gotoh

13 March 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
AIAkira Inoue
Akira Inoue
KYKazushi Yoshida
Kazushi Yoshida
SMSatoshi Morita
Satoshi Morita
FIFumio Imamura
Fumio Imamura
TSTakashi Seto
Takashi Seto
MFMasahiro Fukuoka
Masahiro Fukuoka
The Japan Guidelines of Lung Cancer Therapy recommend epidermal growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent non-small cell lung cancer patients with epidermal growth factor receptor mutation. Although survival periods in recent reports of epidermal growth factor receptor-tyrosine kinase inhibitor treatment have been getting longer, the reasons why are unclear. We investigated the survival, prognostic factors and real-world treatment of non-small cell lung cancer patients with epidermal growth factor receptor mutation in clinical practice. Non-small cell lung cancer patients (n = 1660) who started first-line treatment from January 2008 to December 2012 were enrolled. Patients were diagnosed with epidermal growth factor receptor mutation-positive advanced/recurrent non-small cell lung cancer by histology or cytology samples. The primary objective was to estimate overall survival. The secondary objectives were to determine prognostic factors, real-world treatment patterns and efficacy of gefitinib treatment. We calculated the treatment exposure rate for each treatment category using the following formula: exposure rate = person-years for the treatment category/total person-years × 100. The median overall survival was 30.8 months. Sex, age, histology, epidermal growth factor receptor mutation type, clinical stage and performance status affected overall survival. The exposure rates for all epidermal growth factor receptor-tyrosine kinase inhibitors, gefitinib and platinum-doublet chemotherapy were 62.1, 46.4 and 8.5% respectively. Overall 56.1% of patients were administered gefitinib as first-line therapy, and 39.0% were treated with ≥2 epidermal growth factor receptor-tyrosine kinase inhibitor regimens. The median progression-free survival in the first-line gefitinib group was 11.4 months. Factors affecting prognosis were sex, histology, clinical stage and performance status. Epidermal growth factor receptor-tyrosine kinase inhibitors, especially gefitinib, are major components of the treatment regimens for epidermal growth factor receptor mutation-positive non-small cell lung cancer. Switching and re-challenging with epidermal growth factor receptor-tyrosine kinase inhibitors were also practiced in Japan.

1 April 2016 in Journal of Cancer Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
JOJun Osugi
Jun Osugi
SMSatoshi Muto
Satoshi Muto
YMYuki Matsumura
Yuki Matsumura
MHMitsunori Higuchi
Mitsunori Higuchi
HSHiroyuki Suzuki
Hiroyuki Suzuki
MGMitsukazu Gotoh
Mitsukazu Gotoh
Objective: The present study compared the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), high-sensitivity mGPS (HS-mGPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), prognostic index (PI), and prognostic nutritional index (PNI) in patients with resectable non-small cell lung cancer (NSCLC). Materials and Methods: This retrospective study included 327 consecutive patients with resectable NSCLC with a follow.-up period. >5. years. Initially, the HS-mGPS was directly compared with the GPS and mGPS in terms of their ability to predict survival in patients with resectable NSCLC. Second, inflammation.-based scores, including the HS-mGPS, NLR, PLR, PI, and PNI, were analyzed preoperatively using multivariate Cox analysis. Clinical characteristics reflecting cancer progression were also analyzed. Results: Elevated GPS ( P < 0.001), mGPS ( P < 0.001), and HS-mGPS ( P < 0.001) levels were associated with reduced overall survival. The HS-mGPS ( P < 0.001) was superior to the GPS and mGPS ( P = 0.884) as a prognostic marker of postoperative outcomes. On multivariate Cox analysis, age ( P = 0.026), p-T status ( P < 0.001), p-N status ( P < 0.001), lymphatic vessel invasion ( P = 0.008), and the HS-mGPS ( P = 0.016) were independent prognostic factors for survival. Conclusion: These results suggest that the HS-mGPS might have a greater prognostic impact than the GPS, mGPS, NLR, PLR, PI, or PNI in patients with resectable NSCLC.